

These studies also raise the question of the degree to which the fines imposed have a deterrent effect. Over the past five years, such fines have totalled €780 million: a pittance in comparison to the global revenues of pharmaceutical companies, which reached, for example, \$1.29 trillion in 2021 alone, with the European market accounting for one-quarter of sales (1,12). This disparity, which may explain why the fines imposed by the Commission and national authorities have had little impact, highlights the urgent need for tougher penalties in order to effectively deter companies from employing tactics designed to hinder the market entry and uptake of generics and biosimilars.

©Prescrire

► Translated from *Rev Prescrire* March 2026
Volume 46 N° 509 • Pages 222-224

Selected references from Prescrire's literature search

- 1- Prescrire Editorial Staff "Anti-competitive practices: a very "inventive" pharmaceutical industry" *Prescrire Int* 2025; **34** (273): 223.
- 2- Wachsmann A "Politique brevetaire: entre protection légitime et abus d'exclusion". In: "La Matinale de la DGCCRF: concurrence et innovation dans le domaine des produits de santé" 4 April 2025: 7 pages.
- 3- European Commission "Executive summary of the pharmaceutical sector inquiry report" 8 July 2009: 30 pages.
- 4- Représentation de la Commission Européenne au Luxembourg "La Commission inflige à Teva une amende de 462,6 millions d'euros pour utilisation abusive du système de brevets" 31 October 2024: 5 pages.
- 5- European Commission "Summary of Commission decision of 31 October 2024 relating to a proceeding under Article 102 of the Treaty on the Functioning of the European Union (Case AT.40588-Teva Copaxone)": 4 pages.
- 6- "Case T-19/25: Action brought on 15 January 2025 – Teva Pharmaceutical Industries and Teva Pharmaceuticals Europe v Commission": 2 pages.
- 7- Mesmer H "La pratique décisionnelle de l'autorité dans le secteur pharmaceutique". In: "La Matinale de la DGCCRF: concurrence et innovation dans le domaine des produits de santé" 4 April 2025. Video: 2:03:00.
- 8- Flühmann B et al. "The authorization of non-biological complex drugs (NBCDs) follow-on versions: specific regulatory and interchangeability rules ahead?" *GaBI Journal* 2013; **2** (4): 204-207.
- 9- Prescrire Rédaction "Médicaments "biosimilaires": état des lieux début 2025 en France" *Rev Prescrire* 2025; **25** (496): 107-108.
- 10- EMA "Reflection paper on a tailored clinical approach in biosimilar development-Draft" 17 March 2025: 17 pages.
- 11- IQVIA "Assessing the biosimilar void. Achieving sustainable levels of biosimilar competition in Europe" October 2023: 28 pages.
- 12- LEEM "Bilan économique-édition 2022": 124 pages.
- 13- European Commission "Summary of Commission Decision of 22 July 2024 (...) (Case AT.40577 - VIFOR IV iron products)": 3 pages.

Biotechnologies: proposed European legislation underpinned by a biased approach

● Prescrire has warned the European Commission about the risks associated with reducing the regulatory requirements on drugs and medical devices derived from biotechnology.



In November 2025, Prescrire responded to a public consultation held by the European Commission to seek input on its future European Biotech Act (1). According to the Commission, the objective of this initiative is to "improve the size and competitiveness of the biotechnology sector in the European Union while maintaining high safety standards" in the field of health, as well as those of farming, forestry and industry (2).

Prescrire was critical of the biased nature of some of the questions asked as part of the consultation, which assumed the existence of regulatory obstacles impeding access to biotechnologies and the implicit need to introduce simplification and rationalisation measures. The approach taken by the Commission thus favours the

interests of industry, rather than focusing on the protection of public health and the public interest.

Prescrire also called for drugs and medical devices to be covered by specific legislation rather than as part of an overall biotechnology regulation, given the risks that the use of these health products may pose to patients.

Prescrire emphasised that the reform of the 2017 Medical Devices Regulation is not sufficient to ensure patient safety. The examination of medical devices prior to their market introduction is subcontracted to certification organisations called "notified bodies", most of which are privately operated. Prescrire takes the view that medical devices should be evaluated by a centralised public-sector European agency, as is the case with drugs.

Prescrire called for health products to be covered by more stringent regulatory requirements, in relation to the quality of evidence to be provided and good manufacturing practices. Randomised clinical trials with clinical endpoints that are relevant to patients, such as mortality and quality of life, should be the norm.

The European Commission published the first part of its proposed Biotech Act in December 2025 (3). We will discuss this proposal in a future issue.

©Prescrire

► Translated from *Rev Prescrire* May 2026
Volume 46 N° 511 • Page 387

- References**
- 1- Prescrire Rédaction "Réponse de Prescrire au questionnaire public visant à recueillir des données en vue de l'élaboration de l'acte législatif européen sur les biotechnologies" 6 November 2025: 40 pages.
 - 2- European Commission "Call for evidence for an impact assessment. European Biotech Act" 2025: 5 pages.
 - 3- European Commission "Proposal for a regulation of the European Parliament and of the Council on establishing a framework of measures for strengthening Union's biotechnology and biomanufacturing sectors particularly in the area of health" 16 December 2025: 258 pages.